DAX23.708 +0,8%ESt505.482 +0,7%Top 10 Crypto15,59 +2,4%Dow46.382 +0,1%Nas22.789 +0,7%Bitcoin95.787 +0,3%Euro1,1807 +0,1%Öl66,74 +0,3%Gold3.785 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Volkswagen (VW) vz. 766403 RENK RENK73 Porsche vz. PAG911 Tesla A1CX3T Plug Power A1JA81 Deutsche Telekom 555750 BYD A0M4W9 Apple 865985 Novo Nordisk A3EU6F D-Wave Quantum A3DSV9 Porsche Automobil PAH003 HENSOLDT HAG000 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Warten auf Powell-Rede: DAX fester -- Asiens Börsen schwächer -- Berkshire Hathaway verkauft BYD-Anteile komplett -- Goldpreis, Rüstungsaktien, NVIDIA, Plug Power im Fokus
Top News
DAX mit grünen Vorzeichen: Anleger greifen nach der KI-Rally an der Wall Street auch hierzulande zu DAX mit grünen Vorzeichen: Anleger greifen nach der KI-Rally an der Wall Street auch hierzulande zu
Orsted-Aktie springt an: Unternehmen darf Offshore-Windprojekt fortsetzen Orsted-Aktie springt an: Unternehmen darf Offshore-Windprojekt fortsetzen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Viele Anleger entdecken Europa wieder als Investmentregion. Nutze die möglichen Chancen europäischer Aktien mit diesem günstigen ETF von Amundi!

Soligenix Aktie

Kaufen
Verkaufen
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handeln Smartphone
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2AS7Q

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS8342233074

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNGX

Soligenix Aktien News

DatumMeistgelesen
PR NewswireFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
PR NewswireFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
PR NewswireSoligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
PR NewswireSoligenix Announces Recent Accomplishments and Year End 2023 Financial Results
PR NewswireSoligenix Announces Formation of Behçet's Disease Medical Advisory Board
PR NewswireSoligenix to Present at The Microcap Conference
PR NewswireFDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
PR NewswireSoligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
PR NewswireSoligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
PR Newswire"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
PR NewswireSoligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
PR NewswireSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PR NewswireSoligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
PR NewswireSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PR NewswireSoligenix to Present at The ThinkEquity Conference
PR NewswireSoligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
PR NewswireSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
PR NewswireSoligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
PR NewswireHyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
PR NewswireSoligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
PR NewswireSoligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
PR NewswireSoligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
PR NewswireSoligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
PR NewswireSoligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
PR NewswireSoligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors
PR NewswireSoligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
PR NewswireSoligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
PR NewswireSoligenix Provides Regulatory Update on HyBryte™
PR NewswireSoligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
PR NewswireSoligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
PR NewswireSoligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
PR NewswireSoligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
PR NewswireSoligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
PR NewswireSoligenix Announces Reverse Stock Split
PR NewswireSoligenix Invited to Present at the Virtual Investor Summit Event
PR NewswireSoligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
PR NewswireSoligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge
PR NewswireSoligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
PR NewswireSoligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
PR NewswireSoligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Soligenix News

Soligenix News: auf dieser Seite finden Sie alle Soligenix News und Nachrichten zur Soligenix Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Soligenix News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Soligenix News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.